Glancy Binkow & Goldberg LLP Announces Investigation of Accretive Health,
LOS ANGELES -- March 5, 2013
Glancy Binkow & Goldberg LLP announces that it is investigating potential
claims on behalf of purchasers of the securities of Accretive Health, Inc.
(“Accretive” or the “Company”) (NYSE:AH) concerning possible violations of
federal securities laws. The investigation focuses on allegations that certain
statements issued by Accretive between May 9, 2012 and February 26, 2013 were
false and misleading regarding the Company’s business, operations and
Accretive provides revenue cycle management services for hospitals and
healthcare providers in the United States. The investigation is related to
Accretive’s February 26, 2013 announcement that it will postpone the release
of the Company’s financial results for the fourth quarter and full-year 2012
because it is evaluating the timing of revenue recognition for its revenue
cycle management agreements. In addition, Accretive announced that it was
withdrawing the financial guidance that the Company previously provided on
November 7, 2012. As a result of this news, the price of Accretive shares
declined almost 20%, on heavy trading volume.
If you purchased Accretive securities between May 9, 2012 and February 26,
2013, if you have information or would like to learn more about these claims,
or if you wish to discuss these matters or have any questions concerning this
announcement or your rights or interests with respect to these matters, please
contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, by telephone at
(310) 201-9150, Toll Free at (888) 773-9224, by e-mail to
email@example.com, or visit our website at http://www.glancylaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP
(310) 201-9150 or (888) 773-9224
Press spacebar to pause and continue. Press esc to stop.